高血压左室肥厚患者血浆sTRAIL、sDR4、sDR5水平的变化

摘要

Objective:To determine plasma levels of soluble tumor necrosis factor-related apoptosis inducing ligand (sTRAIL) and its soluble death receptor (sDR4,sDR5) in essential hypertension (EH) patients with left ventricular hypertrophy (LVH).Methods:Enzyme linked immunosorbent assay (ELISA) was used to measure plasma levels of sTRAIL,sDR4 and sDR5 in 50 EH + LVH patients (EH + LVH group),50 EH patients without LVH (EH group) and 50 healthy subjects (healthy control group),and the results were compared and analyzed among three groups.Results:① Compared with healthy control group and EH group,there were significant increase in plasma levels of sTRAIL [(0.95±0.11) ng/ml vs.(1.12±0.86) ng/ml vs.(1.74±1.19) ng/ml],sDR4 [(2.38±0.32)pg/ml vs.(5.63±1.05) pg/ml vs.(8.72±1.14) pg/ml] and sDR5 [(＜ 6 pg/ml) vs.(39.19±8.23) pg/ml vs.(78.21±11.2) pg/ml] in EH + LVH group,P＜0.01 all; and levels of sDR4 and sDR5 in EH group were significantly higher than those of healthy control group (P＜0.01 both),but there was no significant difference in sTRAIL level between the two groups (P＞0.05); ② Pearson correlation analysis indicated that there were significant positive correlation among levels of sTRAIL,sDR4 and sDR5 in EH + LVH patients (r =0.325 ～ 0.410,P＜0.05 or ＜0.01).Conclusion:Plasma levels of sTRAIL,sDR4 and sDR5 may be valuable indexes for prediction of left ventricular hypertrophy in patients with hypertension.%目的:测定高血压左室肥厚患者血浆肿瘤坏死因子相关的凋亡诱导配体(sTRAIL)、及其死亡受体(sDR4、sDR5)水平.方法:用酶联免疫吸附法(ELISA)分别检测50例高血压左室肥厚患者(高血压左室肥厚组)、50例高血压无左室肥厚患者(高血压组)和50例健康人(健康对照组)血浆sTRAIL、sDR4和sDR5水平.结果:①与健康对照组及高血压组比较,高血压左室肥厚组血浆sTRAIL[(0.95±0.11) ng/ml比(1.12±0.86) ng/ml比(1.74±1.19)ng/ml]、sDR4[(2.38±0.32)pg/ml比(5.63±1.05) pg/ml比(8.72±1.14)pg/ml]、sDR5[(＜6 pg/ml)比(39.19±8.23) pg/ml比(78.21±11.2) pg/ml]水平均明显升高(P＜0.01)；且高血压组sDR4、sDR5水平明显高于健康对照组(P＜0.01),sTRAIL水平与健康对照组无明显差异(P＞0.05)；②Pearson相关分析表明,高血压左室肥厚患者sTRAIL、sDR4、sDR5间呈显著的正相关性(r=0.325～0.410,P＜0.05或＜0.01).结论:血浆sTRAIL、sDR4、sDR5水平可能是预测高血压患者左室肥厚有价值的指标之一.